Immunoglobulin E specific for Phleum pratense allergens Phl p 1, Phl p 2, Phl p 5, and Phl p 6 (sIgE (Phl p 1, 2, 5, 6))

Immunoglobulin E (IgE) antibodies specific for Phleum pratense (Timothy grass) allergens Phl p 1, Phl p 2, Phl p 5, and Phl p 6 are the primary mediators of grass pollen-induced allergic disease (Valenta et al., 1992). These antibodies recognize specific protein epitopes on major grass allergens, with Phl p 1 and Phl p 5 being the most clinically significant as they are recognized by over 90% of grass-allergic individuals (Sekerkova et al., 2012). Upon exposure to pollen, these IgE molecules bind to high-affinity FcεRI receptors on mast cells and basophils; subsequent cross-linking by the allergens triggers the release of histamine, leukotrienes, and cytokines (Gould & Sutton, 2008). This physiological cascade results in the symptoms of allergic rhinitis, conjunctivitis, and asthma. Therapeutic strategies targeting these specific IgE antibodies include monoclonal antibodies like Omalizumab, which sequester free IgE, and allergen-specific immunotherapy (AIT), which aims to induce immune tolerance and promote the production of protective IgG4 blocking antibodies (Shamji & Durham, 2017). Monitoring the levels and specificity of these IgE antibodies is essential for component-resolved diagnosis and for assessing the efficacy of desensitization treatments.

Other names

Timothy grass pollen-specific IgEAnti-Phl p 1/2/5/6 IgEGrass pollen-specific IgEPhleum pratense-specific IgE

Drugs targeting these IgE antibodies function by either sequestering circulating IgE to prevent its binding to the high-affinity FcεRI receptor on effector cells (e.g., Omalizumab) or by inducing peripheral immune tolerance through allergen-specific immunotherapy (AIT) (Normansell et al., 2014). AIT facilitates a shift from a Th2-biased immune response to a Th1 or Treg-mediated response, leading to the production of 'blocking' IgG4 antibodies that compete with IgE for allergen epitopes, thereby inhibiting mast cell degranulation and subsequent allergic inflammation (Shamji & Durham, 2017).